U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06894407) titled 'Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma' on March 18.
Brief Summary: This phase I/II device clinical trial investigates the safety and efficacy of GNR-mediated THT in patients with stage 3C/3D/4M1 cutaneous metastatic melanoma unresponsive to systemic checkpoint immunotherapy or in patients who have contraindications to systemic immunotherapy.
The primary objective of the study is to evaluate the safety of THT treatment, with secondary objectives focused on tumor response to treatment.
Patients will receive intra-tumoral GNR injections, followed by NIR light therapy to in...